QuantRx, Fieldtests in DOA test manufacturing and distribution pact:
This article was originally published in Clinica
Drugs-of-abuse (DOA) testing specialists QuantRx Biomedical and Fieldtests have entered a manufacturing and distribution agreement that will see QuantRx exclusively manufacture the Fieldtests ID product line. According to Doylestown, Pennsylvania-based QuantRx, the product line, which is designed to test for narcotic residue, will be available during the second quarter of 2008. The agreement will also see Fieldtests distribute QuantRx's QuikSense DOA products through its sales network. Fieldtests intends to extend the deal to cover QuantRx's RapidSense lateral flow test and OralSense oral fluid collection device when these products become commercially available. Financial details of the deal were not revealed.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.